<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25">There was a non-significant decrease in the average number of apheresis sessions from 1.9 to 1.6 sessions per patient, leading to a reduction in apheresis costs of â‚¬866 and a small decrease in total apheresis time. These findings are less marked than those obtained from non-German sites or those reported in other cost-effectiveness studies with plerixafor [
 <xref ref-type="bibr" rid="CR18">18</xref>].
</p>
